Tenya Therapeutics sees mixed success in HCM gene therapy trial
The US company has said that its treatment for the heart condition was generally well tolerated despite some mild adverse events.
Explore our marketing solutions
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
